# OnCo record zhou-caicun (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/zhou-caicun/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "zhou-caicun" ;
  schema:name "Caicun Zhou"@en ;
  schema:alternateName "caicun-zhou"@en ;
  schema:description "Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients."@en ;
  schema:url <https://onco.cc/people/zhou-caicun/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.shsfkyy.com>, <https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20C%5BAuthor%5D%20Shanghai%20Pulmonary%20Hospital%20ivonescimab>, <https://www.iaslc.org/learn-about-us/board-directors> ;
  onco:tag "leadership", "clinician-scientist", "lung cancer" ;
  schema:jobTitle "Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/> ;
  onco:companies <https://onco.cc/companies/ctong/>, <https://onco.cc/companies/akeso/> ;
  onco:institutions <https://onco.cc/institutions/shanghai-pulmonary-hospital/>, <https://onco.cc/institutions/iaslc/> ;
  onco:trials <https://onco.cc/trials/harmoni-2/> ;
  schema:affiliation <https://onco.cc/institutions/shanghai-pulmonary-hospital/> .